 Treats a population of < 200,000 in the US  Same review and development standards as for a non- orphan product  Numbers of patients in clinical trials.

Slides:

Advertisements

Similar presentations

Presentation for HL7 RCRIM and Clinical Genomics SIG HL7 Working Group Meeting San Diego, CA 21Jan2004.

Advertisements

Susan Boynton, VP, Global Regulatory Affairs, Shire

Oncologic Drugs Advisory Committee

The DMO: Improving the Quality, Quickness and Quantity of Access to Alzheimer’s Disease Treatments By Whitney Davis 2011 WISE Intern University of Arkansas.

Rare Diseases and FDASIA

Targeted Cancer Therapeutics, LLC Investor Presentation.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Regulatory Requirements for Orphan Drugs Delivery Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Professor of Pharmaceutics KLE University, Belgaum, India

Going Beyond the Current Regulatory and Incentives Frameworks A new proposal to foster greater orphan drug development 1.

Have FDA Expedited Programs Shortened Drug Development Timelines? An analysis of newly approved therapies and how FDA expedited programs impacted drug.

Extension Article by Dr Tim Kenny

IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.

What is Genetic Testing? And what is its value? Sherri J. Bale, Ph.D., FACMG President and Clinical Director GeneDx.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Kenneth Sisco, MD, PhD, FCAP Medical Director Quest Diagnostics

Haffner Associates, LLC1 Orphan Drugs – 2011 What’s Happening? Women in BIO Marlene E. Haffner, MD, MPH Office 301.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

Medical Achievements Cancer, AIDS, Stem Cell. Cancer Achievements O Newer drugs seem to be making a bigger difference for small, specific groups of patients,

July 2015 PRABHAVATHI FERNANDES, PhD Founder, President and CEO How the PATH Act Can Rejuvenate Antibiotic R & D.

Presented by: Jason Brown, CPA Date: May 10, 2010 Qualified Therapeutic Discovery Project Tax Credit.

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

NDA ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

RARE / ORPHAN DISEASES “ARE WE READY FOR THE CHANGE THAT WE NEED TO FIND EFFECTIVE TREATMENTS FOR ORPHAN DISEASE?”

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Endocrinologic and metabolic Drugs Advisory Committee September 8, 2004 FDA 2004: Revisiting the 1996 Obesity Drug Guidance David G. Orloff, M.D. Division.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Reducing bottlenecks: Rare-purposing™ Action Duchenne, November 07, 2015 David Cavalla, CSO, Healx.

Pharmacogenetics.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

1 FDA Orphan Drug Designation 101 Gayatri R. Rao MD, JD Director Office of Orphan Products Development (OOPD) FDA October 12, 2012.

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.

Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

CS-1 Regulatory Considerations: PDD Indication for Exelon ® (rivastigmine) Martina Struck, PhD Senior Associate Director Drug Regulatory Affairs Novartis.

Surrogate Endpoints as Measures of Efficacy: Complexities & Limitations FDA Advisory Committee November 18, 2002 Michael D. Hughes, Ph.D. Professor of.

Response, PFS or OS – what is the best endpoint in advanced colorectal cancer? Marc Buyse IDDI, Louvain-la-Neuve & Hasselt University

FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.

Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint

Patient Focused Drug Development An FDA Perspective

Industry Perspective: Expanded Access Programs

Expedited Drug Approval Programs

PHEN Clinical Trials Rally

“New Gene Therapy Treatments Will Carry Whopping Price Tags”

Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.

Bozeman Health Clinical Research

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Regulatory perspective

Speeding access to therapies

Is RA Treatment Addressing the Real Needs of Patients?

PAI Preparation and Readiness

Intermediate-Size Patient Populations INDs: What Are They, When Should They Be Used, and Who May Apply for Them?” Richard Klein, Former Director, FDA.

Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P

Suzanne M. Sensabaugh, MS, MBA

A Time for Change for Managing Patients With VTE Who Have Cancer

Overview of the Orphan Drug Tax Credit

Biomarkers as Endpoints

Presentation transcript:

 Treats a population of < 200,000 in the US  Same review and development standards as for a non- orphan product  Numbers of patients in clinical trials will be smaller  FDA has two special units to deal with orphan products Office of Orphan Products Development/Office of the Commissioner Associate Director for Orphan Products in the Office of New Drugs (OND)/CDER

 7 years exclusive marketing for that drug for that disease  Tax credits for clinical development – 20 yr carry forward; 1 year fall back  Waiver of NDA filing fees ($1.5 million FY 2011)  Grant support - $450,000/annum for 4 years

 More than 7,000 rare diseases  More than 350 drugs for orphan diseases have been developed since 1983  Burgeoning field – large and small companies involved  Money to be made  Review times may be faster as majority of orphan diseases serious or life threatening

 Measure of effect of effect of treatment that may correlate with a real endpoint  No guaranteed relationship  Needs validation  E.g. cholesterol is related to heart disease, but many with high cholesterol do not develop heart disease.  So cholesterol lowering drugs lower cholesterol but that alone does not prevent death. Proof of efficacy in preventing heart disease took 5 years to show.

 May be able to shorten a clinical trial with the us of VALIDATED endpoints  Great interest currently; may not correlate

 Indicates a disease state or some physiological state of the organism  May be used to measure the progression of disease or the effects of treatment  Rheumatoid Factors as a marker for Rheumatoid Arthritis; elevated PSA for prostate cancer  May relate to how a drug will/will not act in the body – KRAS gene expression in Colorectal Cancer

 May assist in identifying high-risk individuals so they can either be treated prior to onset of disease of shortly thereafter  Test must be rapidly available and easy to carry out  Must be validated and related to a positive outcome

 Treatment of Serious or life-threatening illness  Must have meaningful benefit over existing therapies  May utilize a surrogate endpoint that is “reasonably likely…to predict clinical benefit”  May have restricted prescribing  Most likely will have post marketing requirements

 Must address a serious or life threatening illness  Potential to treat unmet need  Multiple meetings with FDA to discuss development plans  Options to submit sections of the NDA/BLA as they are ready

 Begins on submission of NDA/BLA  Shortens review time from 10 months to 6 months  May also have “Fast Track”